Faculty of Science, University of Natural Sciences and Humanities in Siedlce, 3-Maja 54, Siedlce 08-110, Poland.
Department of General and Coordination Chemistry and Crystallography, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Sklodowska University in Lublin, Pl. Marii Curie-Sklodowskiej 3, Lublin 20-031, Poland.
Acta Crystallogr C Struct Chem. 2022 Sep 1;78(Pt 9):462-469. doi: 10.1107/S2053229622007781. Epub 2022 Aug 8.
Two new 1,2,4-triazine-containing sulfonamide derivatives, namely, 4-bromo-N-(5,6-diphenyl-2H-1,2,4-triazin-3-ylidene)benzenesulfonamide, CHBrNOS, 3a, and methyl 2-{[(5,6-diphenyl-1,2,4-triazin-3-yl)sulfamoyl]methyl}benzoate, CHNOS, 3b, which crystallize in the different sulfonimide and sulfonamide tautomeric forms, respectively, were synthesized and characterized by spectroscopic, X-ray diffraction and theoretical calculation methods. Both molecules adopt a very similar conformation of the common part of the structure and the differences occur within the substituents on the sulfonamide group. The amino groups characteristic for the existing tautomeric forms are involved in strong intermolecular N-H...N and N-H...O hydrogen bonds in 3a and 3b, respectively. The Hirshfeld surface analysis showed that H...H contacts constitute a high percentage of the intermolecular interactions. Theoretical calculations at the ab initio DFT/B3LYP/6-311++G(d,p) level showed that the two tautomeric forms observed for 3a and 3b can co-exist in chloroform, ethanol and water solutions, with a distinct predominance of the sulfonamide form; the participation of the sulfonimide form increases with increasing solvent polarity.
两个新的 1,2,4-三嗪基磺酰胺衍生物,即 4-溴-N-(5,6-二苯基-2H-1,2,4-三嗪-3-亚基)苯磺酰胺,CHBrNOS,3a 和 2-[(5,6-二苯基-1,2,4-三嗪-3-基)磺酰胺基]甲基苯甲酸甲酯,CHNOS,3b,分别以不同的磺酰亚胺和磺酰胺互变异构形式结晶,通过光谱、X 射线衍射和理论计算方法进行了合成和表征。两个分子都采用了非常相似的结构共同部分的构象,差异出现在磺酰胺基团上的取代基内。对于现有的互变异构形式特征的氨基参与了 3a 和 3b 中分别强烈的分子间 N-H…N 和 N-H…O 氢键。Hirshfeld 表面分析表明,H…H 接触构成了分子间相互作用的很大一部分。在从头算 DFT/B3LYP/6-311++G(d,p)水平上的理论计算表明,在氯仿、乙醇和水溶液中观察到的两种互变异构形式可以共存,磺酰胺形式明显占主导地位;随着溶剂极性的增加,磺酰亚胺形式的参与增加。